Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

265 trials

NCT07582159
Recruiting
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 · United States · 2 sites
Registry update: 6 Nov 2026
NCT07194980
Recruiting
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 · United States · 1 site
Registry update: 29 Oct 2026
NCT06863402
Recruiting
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Phase 2 · United States · 1 site
Registry update: 2 Oct 2026
NCT07557056
Recruiting
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 · United States · 1 site
Registry update: 15 Oct 2026
NCT06904066
Recruiting
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1 · United States · 1 site
Registry update: 2 Nov 2026
NCT07254793
Recruiting
Prophylactic DLI-X for Leukemia Relapse After HCT
Phase 1 · United States · 1 site
Registry update: 29 Oct 2026
NCT07709000
Recruiting
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Phase 2 · Colombia, Israel · 7 sites
Registry update: 4 Nov 2026
NCT07874451
Recruiting
Real-World Study of BCL-2 Inhibitor-Based Regimens in Chronic Lymphocytic Leukemia
Not applicable · China · 1 site
Registry update: 14 Oct 2026
NCT07691047
Recruiting
Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax
Not applicable · France · 2 sites
Registry update: 13 Oct 2026
NCT07520006
Recruiting
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Phase 1/2 · United States · 9 sites
Registry update: 3 Nov 2026
NCT07734038
Recruiting
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 2 · United States · 1 site
Registry update: 9 Nov 2026
NCT07648264
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Phase 3 · Belgium, Canada, Czechia, Germany, Denmark, Spain, France, United Kingdom, Italy, Poland, United States · 60 sites
Registry update: 14 Oct 2026
NCT07020533
Recruiting
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Phase 1 · United States · 3 sites
Registry update: 23 Oct 2026
2025-524283-38-00
Recruiting
HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment
Phase 3 · Netherlands · 39 sites
Registry update: 28 Aug 2026
NCT07225439
Recruiting
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Phase 1 · United States · 2 sites
Registry update: 9 Sept 2026
NCT07532525
Recruiting
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Phase 1 · United States · 1 site
Registry update: 15 Oct 2026
NCT07508995
Recruiting
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
Phase 2 · United States · 1 site
Registry update: 29 Oct 2026
NCT07727083
Recruiting
Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
Not applicable · China · 1 site
Registry update: 13 Aug 2026
NCT07220187
Recruiting
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
Phase 3 · United States · 62 sites
Registry update: 13 Oct 2026
NCT07516093
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Phase 3 · United States · 6 sites
Registry update: 31 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.